1. Home
  2. ZS vs VTRS Comparison

ZS vs VTRS Comparison

Compare ZS & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zscaler Inc.

ZS

Zscaler Inc.

HOLD

Current Price

$131.66

Market Cap

21.1B

Sector

Technology

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$16.21

Market Cap

18.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZS
VTRS
Founded
2007
1961
Country
United States
United States
Employees
N/A
30000
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.1B
18.7B
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
ZS
VTRS
Price
$131.66
$16.21
Analyst Decision
Buy
Buy
Analyst Count
38
4
Target Price
$264.94
$13.50
AVG Volume (30 Days)
5.4M
8.9M
Earning Date
05-28-2026
05-07-2026
Dividend Yield
N/A
3.21%
EPS Growth
30.77
N/A
EPS
N/A
0.15
Revenue
N/A
$14,299,900,000.00
Revenue This Year
$27.83
$4.41
Revenue Next Year
$19.67
$1.96
P/E Ratio
N/A
$106.97
Revenue Growth
N/A
N/A
52 Week Low
$114.63
$8.63
52 Week High
$336.99
$17.53

Technical Indicators

Market Signals
Indicator
ZS
VTRS
Relative Strength Index (RSI) 48.17 54.70
Support Level $127.90 $16.02
Resistance Level $132.81 $16.54
Average True Range (ATR) 6.37 0.49
MACD 0.42 -0.01
Stochastic Oscillator 94.46 74.29

Price Performance

Historical Comparison
ZS
VTRS

About ZS Zscaler Inc.

Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: